Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Port Jefferson, USA.
BMC Infect Dis. 2020 Feb 24;20(1):175. doi: 10.1186/s12879-020-4894-2.
In patients at high risk of opportunistic infections who present with isolated. neurological symptoms, it is lifesaving to consider Central Nervous System Aspergillosis (CNS-A). Ibrutinib use in chronic lymphocytic leukemia (CLL) has previously been associated with CNS-A. We provide a case report of a patient that presented with primary CNS-A on Ibrutinib therapy without any prior pulmonary or local paranasal signs of infection.
74-year-old Caucasian male with CLL and no prior chemotherapy on ibrutinib for 6 months presented with three months of unsteady gait, occipital headache, and confusion. He has a history of pulmonary sarcoidosis on chronic prednisone 5 mg daily and chronic obstructive pulmonary disease (COPD). He was found to have a "brain abscess" on imaging. Emergent craniotomy confirmed Aspergillus and patient was treated with Voriconazole for 6 months. At six-month follow up, repeat magnetic resonance imaging (MRI) confirmed complete resolution of CNS lesion.
Our case reinforces the importance of being vigilant for isolated CNS-A in CLL patients on ibrutinib who present with neurological symptoms and signs, without prior or co-infection of sino-pulmonary tissue.
对于存在孤立性神经症状且存在机会性感染高危风险的患者,考虑中枢神经系统曲霉病(CNS-A)至关重要。伊布替尼在慢性淋巴细胞白血病(CLL)中的应用以前与 CNS-A 有关。我们提供了一例患者的病例报告,该患者在伊布替尼治疗时出现原发性 CNS-A,而无任何先前的肺部或局部副鼻窦感染迹象。
74 岁白人男性,患有 CLL,在接受伊布替尼治疗 6 个月期间未接受任何先前的化疗,出现 3 个月的步态不稳、枕部头痛和意识模糊。他有慢性泼尼松 5mg 每日治疗的肺结节病和慢性阻塞性肺疾病(COPD)病史。影像学检查发现“脑脓肿”。紧急开颅术证实为曲霉菌,患者接受伏立康唑治疗 6 个月。在 6 个月的随访中,重复磁共振成像(MRI)证实中枢神经系统病变完全消退。
我们的病例再次强调了在伊布替尼治疗的 CLL 患者中,对于出现神经系统症状和体征而无先前或合并的鼻窦肺部感染的孤立性 CNS-A 保持警惕的重要性。